Table 1 Tumour types observed in Zmat3, Puma, p21 compound mutant mice.
From: Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice
Animal # | Sex | Age (days) | Tumour type(s) observed |
|---|---|---|---|
Zmat3−/−;Puma−/− | |||
624 | M | 340 | Early B- (Spl) and T-cell (Thy) lymphoma, infiltration (Liv, Kid, SC) |
471 | M | 323 | B-cell (Spl) and T-cell (Thy) lymphoma, metastasis (Liv, Kid) |
6 M/F | 450–493 | No tumours observed | |
13 M/F | 450–469 | N.D. No tumours observed | |
Zmat3−/−;p21−/− | |||
222 | M | 572 | Hepatocellular carcinoma |
276 | M | 399 | Hepatocellular carcinoma |
283 | F | 470 | Sarcoma |
285 | F | 423 | Sarcoma |
297 | F | 394 | Sarcoma |
293 | M | 400 | Subcutaneous tumour resembling amelanotic melanoma |
831 | M | 400 | Lymphoma (Spl), metastasis (Liv, Kid) |
832 | M | 549 | N.D. Enlarged spleen (0.3 g), mottled liver (0.26 g) observed |
2 M/F | 461–517 | No tumours observed | |
18 M/F | 459–517 | N.D. No tumours observed | |
Zmat3−/−;p21−/−;Puma−/− | |||
615 | M | 245 | Early B-cell (Spl) and T-cell (Thy, MLN) lymphoma |
616 | M | 257 | Early B-cell (Spl) and T-cell (Thy) lymphoma |
696 | F | 133 | Early B-cell (Spl) and T-cell (Thy) lymphoma |
454 | F | 430 | B-cell lymphoma (Spl), myeloid tumour (SC/BM) |
473 | F | 345 | B-cell lymphoma (Liv) |
507 | M | 374 | B-cell (Spl) and T-cell (MLN) lymphoma, metastasis (L, Spl) |
773 | M | 218 | B-cell (Thy, LN) and T-cell (Spl) lymphoma |
187 | F | 506 | N.D. Splenomegaly (2.9 g) observed |
651 | F | 453 | Follicular hyperplasia (Spl) |
562 | F | 373 | Myelogenous leukaemia |
10 M/F | 450–590 | N.D, No tumours observed | |
WT | |||
12 M/F | 438–508 | No tumours observed | |
Trp53−/− | |||
14 M/F | 83–424 | N.D. 5x thymic lymphoma, 8x lymphoma, 1x solid tumour | |
